{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibhxehfwofomnrxtdymngs5prik4laubdtsh7o34igcxfu4cgoata",
    "uri": "at://did:plc:nnaxwirbqywidimahadp42bj/app.bsky.feed.post/3mkj23u4j32o2"
  },
  "path": "/prothena-announces-novo-nordisk-obtains-fast-track-designation-from-the-u-s-fda-for-coramitug-prx004-in-attr-amyloidosis-with-cardiomyopathy/",
  "publishedAt": "2026-04-27T21:02:26.000Z",
  "site": "https://www.cityam.com",
  "tags": [
    "Business Update"
  ],
  "textContent": "Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 CLEOPATTRA clinical trial in ~1280 participants with ATTR-CM; primary completion expected in 2029 The Fast Track Designation underscores the unmet need within ATTR-CM and could expedite the review of coramitug",
  "title": "Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy"
}